Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Padmanee Sharma

Showing results (211-220 of 216) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 216 results.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Nature|January 17, 2020
B cells and tertiary lymphoid structures promote immunotherapy responseBeth A Helmink, Sangeetha M Reddy, Jianjun Gao, et al.
Nature|August 20, 2025
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapyErez N Baruch, Frederico O Gleber-Netto, Priyadharsini Nagarajan, et al.
Nature Medicine|July 9, 2021
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeMiles C Andrews, Connie P M Duong, Vancheswaran Gopalakrishnan, et al.
Science (New York, N.Y.)|December 23, 2021
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy responseChristine N Spencer, Jennifer L McQuade, Vancheswaran Gopalakrishnan, et al.
Journal of Translational Medicine|December 16, 2011
Defining the critical hurdles in cancer immunotherapyBernard A Fox, Dolores J Schendel, Lisa H Butterfield, et al.
Pageof 22

Showing results (211-220 of 216) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 216 results.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Nature|January 17, 2020
B cells and tertiary lymphoid structures promote immunotherapy responseBeth A Helmink, Sangeetha M Reddy, Jianjun Gao, et al.
Nature|August 20, 2025
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapyErez N Baruch, Frederico O Gleber-Netto, Priyadharsini Nagarajan, et al.
Nature Medicine|July 9, 2021
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeMiles C Andrews, Connie P M Duong, Vancheswaran Gopalakrishnan, et al.
Science (New York, N.Y.)|December 23, 2021
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy responseChristine N Spencer, Jennifer L McQuade, Vancheswaran Gopalakrishnan, et al.
Journal of Translational Medicine|December 16, 2011
Defining the critical hurdles in cancer immunotherapyBernard A Fox, Dolores J Schendel, Lisa H Butterfield, et al.
Pageof 22